Filing Details
- Accession Number:
- 0001209191-20-040351
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-02 16:36:43
- Reporting Period:
- 2020-07-01
- Accepted Time:
- 2020-07-02 16:36:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1426332 | Ngm Biopharmaceuticals Inc | NGM | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1642996 | Jin-Long Chen | 333 Oyster Point Boulevard South San Francisco CA 94080 | Chief Scientific Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-07-01 | 17,737 | $18.79 | 1,027,268 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-07-01 | 7,263 | $19.20 | 1,020,005 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.105 to $19.095. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.315. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
